147 related articles for article (PubMed ID: 37158890)
1. Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study.
Epperla N; Welkie RL; Torka P; Shouse G; Karmali R; Shea L; Anampa-Guzmán A; Oh TS; Reaves H; Tavakkoli M; Lindsey K; Greenwell IB; Hansinger E; Thomas C; Chowdhury SM; Annunzio K; Christian B; Barta SK; Geethakumari PR; Bartlett NL; Herrera AF; Grover NS; Olszewski AJ
J Hematol Oncol; 2023 May; 16(1):49. PubMed ID: 37158890
[TBL] [Abstract][Full Text] [Related]
2. Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life.
Sortais C; Lok A; Tessoulin B; Gastinne T; Mahé B; Dubruille V; Blin N; Touzeau C; Moreau A; Bossard C; Peterlin P; Garnier A; Guillaume T; Le Bourgeois A; Chevallier P; Moreau P; Leux C; Le Gouill S
Ann Hematol; 2020 Jul; 99(7):1595-1604. PubMed ID: 32417940
[TBL] [Abstract][Full Text] [Related]
3. Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study.
Epperla N; Zhao Q; Karmali R; Torka P; Shea L; Oh TS; Anampa-Guzmán A; Reves H; Tavakkoli M; Greenwell IB; Hansinger E; Umyarova E; Annunzio K; Sawalha Y; Christian B; Thomas C; Barta SK; Geethakumari PR; Bartlett NL; Grover NS; Olszewski AJ
Blood Adv; 2023 Sep; 7(17):5038-5046. PubMed ID: 37315169
[TBL] [Abstract][Full Text] [Related]
4. Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study.
Luminari S; Merli M; Rattotti S; Tarantino V; Marcheselli L; Cavallo F; Varettoni M; Bianchi B; Merli F; Tedeschi A; Cabras G; Re F; Visco C; Torresan Delamain M; Cencini E; Spina M; Ferrero S; Ferrari A; Deodato M; Mannina D; Annibali O; Rago A; Orsucci L; Defrancesco I; Frigeni M; Cesaretti M; Arcaini L
Blood; 2019 Sep; 134(10):798-801. PubMed ID: 31292118
[TBL] [Abstract][Full Text] [Related]
5. Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome.
Muntañola A; Mozas P; Mercadal S; Huguet M; Bobillo S; Bastos-Oreiro M; Jiménez-Ubieto A; Rovira J; Rivero A; Tolosa C; Luizaga L; de Villambrosia SG; Novelli S; Caballero D; Salar A; Alonso-Álvarez S; Magnano L; Gutiérrez NC; Sancho JM; López-Guillermo A;
Br J Haematol; 2023 Feb; 200(3):306-314. PubMed ID: 36261137
[TBL] [Abstract][Full Text] [Related]
6. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy.
Jurinovic V; Kridel R; Staiger AM; Szczepanowski M; Horn H; Dreyling MH; Rosenwald A; Ott G; Klapper W; Zelenetz AD; Barr PM; Friedberg JW; Ansell S; Sehn LH; Connors JM; Gascoyne RD; Hiddemann W; Unterhalt M; Weinstock DM; Weigert O
Blood; 2016 Aug; 128(8):1112-20. PubMed ID: 27418643
[TBL] [Abstract][Full Text] [Related]
7. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.
Casulo C; Dixon JG; Le-Rademacher J; Hoster E; Hochster HS; Hiddemann W; Marcus R; Kimby E; Herold M; Sebban C; Gyan E; Foon K; Nielsen T; Vitolo U; Salles GA; Shi Q; Flowers CR
Blood; 2022 Mar; 139(11):1684-1693. PubMed ID: 34614146
[TBL] [Abstract][Full Text] [Related]
8. Rituximab and Chemotherapy for Newly Diagnosed Follicular Lymphoma: Real-World Report of Polish Lymphoma Research Group.
Paszkiewicz-Kozik E; Debowska M; Jakacka N; Kotarska M; Szymanski M; Wisniewski K; Konska A; Jarzembowska M; Drozd-Sokolowska J; Romejko-Jarosinska J; Szumera-Cieckiewicz A; Rymkiewicz G; Ziarkiewicz-Wroblewska B; Lech-Maranda E; Walewski J; Hus I
Chemotherapy; 2022; 67(4):201-210. PubMed ID: 35249035
[TBL] [Abstract][Full Text] [Related]
9. [The prognostic significance of POD24 in 106 cases with splenic marginal lymphoma with bone marrow invasion].
Lyu R; Yan YT; Yi SH; Wang TY; Deng SH; Liu W; Huang WY; An G; Sui WW; Zou DH; Qiu LG; Li ZJ
Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):228-233. PubMed ID: 32311893
[No Abstract] [Full Text] [Related]
10. Survival Outcomes of Patients with Follicular Lymphoma after Relapse or Progression: A Single-Center Real-World Data Analysis.
Lee YP; Lee MS; Yoon SE; Cho J; Bang YH; Shim JH; Kim WS; Kim SJ
J Oncol; 2022; 2022():2263217. PubMed ID: 36199784
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK).
Moccia AA; Schär S; Hayoz S; Pirosa MC; Taverna C; Novak U; Kimby E; Ghielmini M; Zucca E
Br J Haematol; 2021 Mar; 192(6):1031-1034. PubMed ID: 32805081
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial.
Grunenberg A; Kaiser LM; Woelfle S; Schmelzle B; Viardot A; Möller P; Barth TFE; Muche R; Dreyhaupt J; Raderer M; Kiesewetter B; Buske C
BMC Cancer; 2021 Jun; 21(1):749. PubMed ID: 34187401
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of prognosis following early disease progression in peripheral T-cell lymphoma.
Suzuki Y; Yano T; Suehiro Y; Iwasaki H; Hidaka M; Otsuka M; Sunami K; Ikeda H; Sawamura M; Ito T; Iida H; Nagai H
Int J Hematol; 2020 Dec; 112(6):817-824. PubMed ID: 32886278
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.
Oh SY; Kim WS; Kim JS; Kim SJ; Yoon DH; Yang DH; Lee WS; Kim HJ; Yhim HY; Jeong SH; Won JH; Lee S; Kong JH; Lim SN; Ji JH; Kwon KA; Lee GW; Lee JH; Lee HS; Shin HJ; Suh C
Cancer Commun (Lond); 2019 Oct; 39(1):58. PubMed ID: 31619290
[TBL] [Abstract][Full Text] [Related]
15. Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma.
Freeman CL; Kridel R; Moccia AA; Savage KJ; Villa DR; Scott DW; Gerrie AS; Ferguson D; Cafferty F; Slack GW; Farinha P; Skinnider B; Connors JM; Sehn LH
Blood; 2019 Aug; 134(9):761-764. PubMed ID: 31300404
[TBL] [Abstract][Full Text] [Related]
16. Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma.
Sorigue M; Bishton M; Domingo-Domenech E; McMillan A; Prusila R; García O; Kuusisto M; Condom M; Tapia G; Ribera JM; Kuittinen O; Fox CP; Sancho JM
Leuk Lymphoma; 2019 Oct; 60(10):2524-2531. PubMed ID: 30942640
[TBL] [Abstract][Full Text] [Related]
17. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
[TBL] [Abstract][Full Text] [Related]
18. [Clinical features and outcomes of newly diagnosed follicular lymphoma concurrent with diffuse large B-cell lymphoma component].
Lin ZJ; Zha J; Yi SH; Li ZF; Ping LY; He XH; Yu HF; Zheng Z; Xu W; Chen FL; Xie Y; Chen BY; Zhang HL; Wang L; Ding KY; Li WY; Yang HY; Zhao WL; Qiu LG; Li ZM; Song YQ; Xu B
Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):456-462. PubMed ID: 35968587
[No Abstract] [Full Text] [Related]
19. Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months.
Yoon SE; Cho J; Kim WS; Kim SJ
J Cancer; 2021; 12(9):2488-2497. PubMed ID: 33854610
[No Abstract] [Full Text] [Related]
20. Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma.
Teckie S; Qi S; Chelius M; Lovie S; Hsu M; Noy A; Portlock C; Yahalom J
Ann Oncol; 2017 May; 28(5):1064-1069. PubMed ID: 28327924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
